// Biotech and Pharma Therapeutics
Pharma eyes male birth control pill for Gen Z
September 30, 2024 / Drug Developers / Male Birth Control / Non-hormonal Contraception / YourChoice Therapeutics
Drug developers are pursuing male birth control options, focusing on Gen Z, with non-hormonal methods like YourChoice Therapeutics’ vitamin A-based pill. Despite challenges, the growing demand and shifting reproductive responsibility could lead to a significant market.
Addressing ‘techquity’ at Children’s National Hospital
October 1, 2024 / Telemedicine Equity / Digital Health / Telehealth Access
Children’s National Hospital addresses “”techquity”” by providing subsidized smartphones with data plans to low-income families, improving telemedicine access. This initiative reduced barriers to care, decreased no-show rates, and enhanced patient-provider satisfaction.
The top biopharma conferences in 2025
October 1, 2024 / Biopharma Conferences / Clinical Trial Results 2025 / Regulatory Approvals
Top biopharma conferences in 2025 will showcase key clinical trial results, including Alzheimer’s, liver diseases, cardiology, and cancer treatments. Major events like ASCO, AHA, and BIO will drive scientific discovery, partnerships, and regulatory progress.
Roche in place to seize obesity opportunities, company says
October 1, 2024 / Roche Obesity Strategy / Cardiovascular Renal Metabolism Therapies / Obesity Drug Market Opportunities / Metabolic
Roche is strategically positioning itself to capitalize on the growing obesity market, focusing on cardiovascular, renal, and metabolic diseases, alongside its core areas in neurology, oncology, immunology, and ophthalmology.
Staff Safety is Key to Sustaining Home Health Growth
October 1, 2024 / Home Health Worker Safety / Healthcare
Home health care’s growth relies on ensuring staff safety. With rising risks of violence, adopting real-time support technologies like duress buttons is crucial to protecting caregivers and sustaining the shift to home-based care.
// 4th Industrial Revolution
Frontier Bio’s Lab-Grown Lungs Offers Hope for Drug Development
October 1, 2024 / Lab-grown Lung Tissue / Frontier Bio / 3D Bioprinting / Drug Testing / Stem Cell Lung Regeneration / Drug Development
Frontier Bio has developed lab-grown lung tissue using 3D bioprinting and stem cells, offering a precise model for drug development. This breakthrough improves disease research, drug testing, and may aid in organ transplantation solutions.
AI-powered surgery technology at UW Harborview shows big returns
September 30, 2024 / AI / Surgical Guidance / Proprio Paradigm Surgery / Spinal Surgery / AI / Orthopedic Surgery
UW Harborview’s use of Proprio’s AI-powered surgical platform, Paradigm, successfully completed 50 surgeries, improving implant accuracy, reducing radiation, and enhancing real-time tracking during spinal procedures, surpassing traditional navigation methods.
OpenAI Academy launches to invest in developers, organizations using AI
September 30, 2024 / OpenAI Academy / AI Development Investment / Global AI Talent Training
OpenAI Academy aims to invest in developers and organizations using AI to address challenges in low- and middle-income countries. The initiative provides AI training, $1 million in API credits, and fosters innovation in sectors like healthcare, education, and agriculture.
How AI Is Transforming Rehabilitation Healthcare Administration
September 30, 2024 / AI in Rehabilitation Healthcare / Patient Care / Billing Automation / Clinical Burnout
AI is transforming rehabilitation healthcare administration by optimizing workflows, reducing administrative burdens, and improving patient care. It enhances predictive scheduling, data-driven decisions, and billing processes, reducing burnout and improving outcomes while maintaining human expertise in clinical care.
Avo Launches EHR-Integrated AI Consult Tool
September 30, 2024 / AI Tool / Healthcare AI Adoption / Clinical Decisio Support
Avo’s AI tool, Ask Avo, integrates seamlessly into EHR systems, offering clinicians real-time support for patient chart summaries, care gap analyses, and order placements. It enhances decision-making with customizable, accurate, and transparent clinical responses.
// Business & Markets
IGM lays off staff in autoimmune pivot; Metsera ramps up obesity drug supply
October 1, 2024 / IGM Autoimmune Pivot / Metsera Obesity Drug Production / Moderna Norovirus Vaccine Trial / Biotech Strategic Reviews
IGM Biosciences shifts focus to autoimmune diseases, laying off staff to reduce oncology spending. Meanwhile, Metsera boosts obesity drug production with a manufacturing deal, and Moderna begins a Phase 3 trial for its norovirus vaccine.
23andMe CEO Wojcicki no longer open to third-party takeover proposals, filing shows
September 30, 2024 / 23andMe going private /CEO Acquisition / Stock Buyout
23andMe CEO Anne Wojcicki announced she is no longer open to third-party takeover proposals and plans to take the company private. Earlier, she offered to acquire remaining shares after the independent directors resigned over unsatisfactory offers.
Kailera Therapeutics emerges from stealth with $400M for obesity drugs
October 1, 2024 / Kailera Therapeutics obesity drugs / Weight Loss / GLP-1 Agonists / Clinical Trials / Metabolic Disease Drug Development
Kailera Therapeutics emerged from stealth with $400M to develop GLP-1 drugs for obesity and metabolic conditions, led by biotech veteran Ron Renaud. Its lead program, KAI-9531, targets GLP-1 and GIP receptors and is in clinical trials.
Nym Raises $47M to Expand Autonomous Medical Coding Engine
October 1, 2024 / NYM Autonomous Medical Coding / AI-driven Revenue Cyle Management
Nym raised $47M to expand its AI-powered autonomous medical coding engine, which enhances coding accuracy, reduces costs, and accelerates revenue cycle management in healthcare. The system processes medical charts instantly, minimizing errors and administrative burdens.
Genentech buys Regor’s next-gen CDK inhibitors for $850M
September 30, 2024 / Genentech Regor CDK Inhibitors / Breast Cancer Treatment / Regor Therapeutics Oncology
Genentech acquired Regor Therapeutics’ portfolio of next-gen CDK inhibitors for $850M, targeting breast cancer treatment. The deal includes potential milestone payments, with Regor’s lead product, RGT-419B, showing promising efficacy as a monotherapy in early trials.
// Legal & Regulatory
Epic Declines to Appeal Carequality Resolution in Dispute with Particle Health
October 1, 2024 / Epic Systems / Particle Health Dispute / Patient Record Interoperability / Healthcare Data Privacy Dispute
Epic Systems will not appeal the Carequality Steering Committee’s resolution in its patient data privacy dispute with Particle Health. Epic urges transparency, calling for the full release of the resolution to restore trust in healthcare data interoperability.
Patients sue over alleged stomach paralysis linked to Ozempic, Mounjaro
September 30, 2024 / Ozempic Lawsuit Gastroparesis / Mounjaro Stomach Paralysis Case / Novo Nordisk / Eli Lilly / Litigation
Thousands, including Dana Filmore, are suing Novo Nordisk and Eli Lilly, alleging that diabetes drugs Ozempic and Mounjaro caused gastroparesis (stomach paralysis). The lawsuit claims the companies failed to warn patients about this risk, with trial expected in 2025.
BMS skates again on $6.4B Celgene shareholder lawsuit but is still not free from another filing
October 1, 2024 / BMS Celgene shareholder lawsuit / FDA Approval Delay / Bristol Myers Squibb / Legal Battle
A federal judge dismissed a $6.4 billion lawsuit claiming Bristol Myers Squibb (BMS) delayed FDA approval of Breyanzi to avoid paying Celgene shareholders. The lawsuit could be refiled by a properly appointed trustee. BMS continues to expand Breyanzi’s indications.
Johnson & Johnson suspends rebate plan after federal intervention
October 1, 2024 / Johnson & Johnson / Pharmaceutical Pricing Agreement / Drug Pricing / Xarelto Discount Policy
Johnson & Johnson has halted its 340B rebate model, following HRSA’s intervention to protect patient access to Stelara and Xarelto. The proposed rebate system aimed to replace traditional upfront discounts with a rebate-based structure.
Judge dismisses $6.4 billion lawsuit against Bristol Myers Squibb
October 1, 2024 / Bristol Myers Squibb Lawsuit / Celgene Acquisition Lawsuit / Breyanzi Approval Delay / CVR Payments Lawsuit / Cancer Therapy Legal Case
A judge dismissed a $6.4 billion lawsuit against Bristol Myers Squibb, which alleged delayed drug approvals to avoid contingent value right (CVR) payments related to its 2019 acquisition of Celgene and therapies like Breyanzi.
// Research & Development
Moderna doses first subject in Phase III trial of mRNA norovirus vaccine in US
October 1, 2024 / Moderna mRNA Norovirus Vaccine / Nova 301 Clinical Trial / mRNA-1403 Efficacy / Norovirus Vaccine
Moderna initiated its Phase III trial for the mRNA norovirus vaccine, mRNA-1403, enrolling 25,000 adults globally to assess its efficacy against moderate to severe gastroenteritis. The trial focuses on older adults, particularly those over 60.
mRNA Covid-19 vaccines may boost cancer immunotherapy effectiveness
September 30, 2024 / mRNA Covid-19 / Cancer Therapy / Immune Checkpoint Inhibitors / mRNA Vaccine
A study presented at ESMO 2024 revealed that mRNA Covid-19 vaccines may enhance the effectiveness of immune checkpoint inhibitors in advanced lung cancer patients, showing improved survival rates compared to unvaccinated patients. Prospective studies will explore these findings further.
Kezar Life Sciences pauses trial for lupus treatment after patient deaths
September 30, 2024 / Kezar Life Sciences / Lupus Trial / Zetomipzodmidb Safety Review / FDA Trial Safety Concerns
Kezar Life Sciences paused its mid-stage lupus nephritis trial after four patient deaths, prompting safety reviews. The independent committee recommended halting enrollment and dosing, with three fatalities showing symptoms close to zetomipzomib administration.
Gene-Editing Biotech Prime Medicine Strikes Up Cell Therapy R&D Alliance With Bristol Myers Squibb
September 30, 2024 / Prime Medicine BMS Partnership / Gene-editing T Cell Therapies / Onoclogy / Ex Vivo Cell Therapy R&D / BMS Immunology Collaboration
Prime Medicine has partnered with Bristol Myers Squibb to develop next-generation ex vivo T cell therapies using its precise gene-editing technology. The deal includes $110 million upfront, with potential milestone payments exceeding $3.5 billion.
Kezar halts dosing and enrollment in key lupus study after 4 patient deaths
September 30, 2024 / Kezar Life Sciences / Trials Halted / Patient Deaths / Study Suspention
Kezar Life Sciences paused its Phase 2b lupus nephritis trial of zetomipzomib after four patient deaths, following safety concerns. The trial suspension comes after an independent review showed a pattern of symptoms linked to dosing proximity.
// Politics
Sens. Warner & Wyden seek healthcare cybersecurity mandates in new bill
September 27, 2024 / Healthcare Cybersecurity Mandates / Health Infastructure Security and Accountability Act / Data Protection Reforms / Cybersecurity Funding
Senators Warner and Wyden introduced a bill mandating stronger cybersecurity protocols in healthcare, targeting large entities while providing funding for rural hospitals. The bill aims to replace voluntary standards with enforceable requirements to protect patient data and care continuity.
BIOSECURE Act: US to Target Chinese Biotechnology Companies
September 26, 2024 / Biosecure Act / China Biotech / WuXi AppTec US Ban / Genetic Data Security Risks
The BIOSECURE Act, passed by the U.S. House, seeks to block U.S. federal funding for partnerships with Chinese biotech companies like WuXi AppTec and BGI, citing national security concerns and risks of genetic data misuse.
Overdue and underwhelming: House GOP skips key China bills during ‘China Week’
September 26, 2024 / Biosecure Act China / Biotech Restrictions / Wall Street China Investments / China Tariff Loophole / China Military Tech Funding
During “”China Week,”” the House passed bipartisan legislation like the BIOSECURE Act, targeting Chinese biotechnology companies linked to military threats. However, key measures on U.S. investments in Chinese military technology and tariff loopholes were omitted.
As urged by the AHA and others, J&J tells HRSA it is abandoning proposed 340B rebate plan
September 30, 2024 / Johnson & Johnson 340B Rebate Plan / Stelara Xarelto 340B Pricing / 340B Program Hospital Impact
Johnson & Johnson abandoned its 340B rebate model after pressure from HRSA and bipartisan lawmakers, avoiding penalties. The plan, which shifted from upfront discounts to rebates on Stelara and Xarelto, faced criticism for potentially harming 340B hospitals.
CDMOs eye industrywide growth in 2025 as many spurn BIOSECURE Act, CPHI research shows
September 30, 2024 / CDMO Market Growth 2025 / Biosecure Act Opposition / GLP-1 Therapy Demand / CDMO Inducstry Challenges
Despite some industry resistance to the BIOSECURE Act, 49% of CDMOs anticipate growth in 2025, with GLP-1 therapies driving demand. However, early-stage projects still face funding challenges, hindering smaller biotech collaborations.